难治性抑郁症与外周C反应蛋白
该研究纳入102例难治性抑郁症、48例治疗有效且当前无抑郁、48例未用药抑郁患者及54名健康对照,检测高敏C反应蛋白(CRP)等指标;校正BMI后难治组CRP较健康对照显著升高(P=0.007,d=0.47),治疗有效组(d=0.29)和未用药组(d=0.18)升高不显著。
要点
- 难治性抑郁症患者BMI校正后CRP较健康对照显著升高(P=0.007,d=0.47)。
- 治疗有效组(d=0.29)和未用药组(d=0.18)CRP升高不显著。
- 与CRP相关的临床表型包括植物性抑郁症状、BMI、状态焦虑和童年逆境。
核心结论
- 难治性抑郁症患者BMI校正后CRP较健康对照显著升高(P=0.007,d=0.47)。
- 治疗有效组(d=0.29)和未用药组(d=0.18)CRP较健康对照升高不显著。
- 植物性抑郁症状、BMI、状态焦虑和童年逆境等表型与CRP升高相关。
研究设计与样本
- 研究纳入102例当前抑郁的难治性抑郁症患者、48例治疗有效且当前无抑郁的患者、48例未用药抑郁患者和54名健康志愿者。
- 检测外周静脉血高敏CRP、BMI,并用问卷评估抑郁、焦虑和童年创伤。
- 采用偏最小二乘(PLS)分析探索CRP与特定临床表型的关系。
主要发现
- BMI校正后CRP在难治组较健康对照显著升高(P=0.007;Cohen's d=0.47)。
- 治疗有效组(d=0.29)和未用药组(d=0.18)CRP较健康对照升高不显著。
- PLS得到最优两因子解,解释临床测量34.7%的变异和CRP 36.0%的变异。
- 与CRP关联最强且在第一PLS成分上权重高的表型为植物性抑郁症状、BMI、状态焦虑和童年感受不被爱或希望拥有不同童年。
临床怎么用
- 对难治性抑郁症患者可考虑检测外周CRP等促炎生物标志物以识别特定临床表型。
- 伴有童年逆境、植物性抑郁症状、状态焦虑或BMI升高的患者CRP可能更高。
- CRP升高的难治性抑郁症患者可能对二线抗炎药物治疗有反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: C-reactive protein (CRP) is a candidate biomarker for major depressive disorder (MDD), but it is unclear how peripheral CRP levels relate to the heterogeneous clinical phenotypes of the disorder.AimTo explore CRP in MDD and its phenotypic associations. METHOD: We recruited 102 treatment-resistant patients with MDD currently experiencing depression, 48 treatment-responsive patients with MDD not currently experiencing depression, 48 patients with depression who were not receiving medication and 54 healthy volunteers. High-sensitivity CRP in peripheral venous blood, body mass index (BMI) and questionnaire assessments of depression, anxiety and childhood trauma were measured. Group differences in CRP were estimated, and partial least squares (PLS) analysis explored the relationships between CRP and specific clinical phenotypes. RESULTS: Compared with healthy volunteers, BMI-corrected CRP was significantly elevated in the treatment-resistant group (P = 0.007; Cohen's d = 0.47); but not significantly so in the treatment-responsive (d = 0.29) and untreated (d = 0.18) groups. PLS yielded an optimal two-factor solution that accounted for 34.7% of variation in clinical measures and for 36.0% of variation in CRP. Clinical phenotypes most strongly associated with CRP and heavily weighted on the first PLS component were vegetative depressive symptoms, BMI, state anxiety and feeling unloved as a child or wishing for a different childhood. CONCLUSIONS: CRP was elevated in patients with MDD, and more so in treatment-resistant patients. Other phenotypes associated with elevated CRP included childhood adversity and specific depressive and anxious symptoms. We suggest that patients with MDD stratified for proinflammatory biomarkers, like CRP, have a distinctive clinical profile that might be responsive to second-line treatment with anti-inflammatory drugs.Declaration of interestS.R.C. consults for Cambridge Cognition and Shire; and his input in this project was funded by a Wellcome Trust Clinical Fellowship (110049/Z/15/Z). E.T.B. is employed half time by the University of Cambridge and half time by GlaxoSmithKline; he holds stock in GlaxoSmithKline. In the past 3 years, P.J.C. has served on an advisory board for Lundbeck. N.A.H. consults for GlaxoSmithKline. P.d.B., D.N.C.J. and W.C.D. are employees of Janssen Research & Development, LLC., of Johnson & Johnson, and hold stock in Johnson & Johnson. The other authors report no financial disclosures or potential conflicts of interest.
引用
- Chamberlain SR, Cavanagh J, de Boer P, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2018. PMID: 29764522. doi:10.1192/bjp.2018.66
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。